Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis

Atopic dermatitis (AD) is a common inflammatory skin disorder that manifests as eczematous lesions, often associated with allergic rhinitis and asthma. Historically, moderate-to-severe disease has been managed with systemic immunosuppression, such as oral corticosteroids, which result in relapse and...

Full description

Saved in:
Bibliographic Details
Published in:Clinical, cosmetic and investigational dermatology cosmetic and investigational dermatology, 2018-01, Vol.11, p.41-49
Main Authors: Awosika, Olabola, Kim, Lori, Mazhar, Momina, Rengifo-Pardo, Monica, Ehrlich, Alison
Format: Article
Language:English
Subjects:
Adults
Advertising executives
Analysis
Antibodies
Asthma
Atopic dermatitis
biologics
Clinical trials
Corticosteroid drugs
Cytokines
Dermatitis
dupilumab
Eczema
Gene expression
Hypertension
IL-13
IL-4
Immunotherapy
Inflammation
Interleukins
Kinases
Light therapy
Monoclonal antibodies
Pathogenesis
Peptides
Quality of life
Review
Rhinitis
Skin
Skin diseases
Steroids (Organic compounds)
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Atopic dermatitis (AD) is a common inflammatory skin disorder that manifests as eczematous lesions, often associated with allergic rhinitis and asthma. Historically, moderate-to-severe disease has been managed with systemic immunosuppression, such as oral corticosteroids, which result in relapse and limiting side effects. Due to recent advancements in the identification of interleukin (IL)-4 and IL-13 as key mediators in AD, new biological agents have been developed for treatment. Dupilumab is a recently approved monoclonal antibody that targets the alpha subunit of the IL-4 receptor and, thus, downregulates activity of IL-4 and IL-13. This review discusses the profile of dupilumab and its potential for efficacy and safety in treating moderate-to-severe AD by reviewing data from Phase I-III clinical trials. Results suggest that dupilumab shows great therapeutic promise for AD. Further studies investigating extended use of dupilumab and dupilumab in comparison to other agents are needed to establish long-term efficacy and safety.
ISSN:1178-7015
1178-7015
DOI:10.2147/CCID.S123329